Harbinger Health Appoints Vincent Lozada as Chief Financial Officer
Harbinger Health, a biotechnology company pioneering the detection of early cancer, announced today the appointment of Vincent Lozada as Chief Financial Officer. Mr. Lozada, who will oversee all financial matters and help lead the effort to build and scale operations including the clinical lab, brings nearly 20 years of healthcare and technology investment banking and corporate finance experience to Harbinger.
“Vince is a welcome addition to the executive leadership team at Harbinger where his exceptional depth of financial, strategic, and leadership experience in the healthcare and technology fields will be instrumental to our near- and long-term growth,” said Stephen Hahn, M.D., CEO of Harbinger Health. “Vince joins us at an important time, as we look to rapidly scale the organization and continue to develop and validate our technology for blood-based early cancer detection with the ultimate aim of creating a paradigm where simple, highly accurate, and reliable cancer screening is accessible to all.”
Mr. Lozada most recently served as Managing Director, Healthcare Investment Banking at RBC Capital Markets, where he advised biotechnology companies on mergers, acquisitions, partnerships, and financings, including initial public offerings, common stock offerings, convertible debt offerings and high-yield debt offerings. Prior to joining RBC Capital Markets in 2016, Mr. Lozada spent nine years at Credit Suisse in roles of increasing responsibility within the Healthcare and Technology Mergers & Acquisitions organizations. Earlier in his career, Mr. Lozada was a member of the Technology Investment Banking team at BofA Securities. He has completed more than 70 strategic and financing transactions valued at approximately $75 billion over the course of his 20 years in the industry. Mr. Lozada holds an M.B.A. from the University of Chicago’s Booth School of Business and a B.S. in Finance from Rutgers. He is also a Chartered Financial Analyst (CFA) charter holder.
“Harbinger is advancing a technology platform that is poised to upend the early cancer detection field as it exists today and bring tremendous value to people, society, and our investors,” said Vincent Lozada, CFO of Harbinger Health. “I am enthusiastic about joining Harbinger and helping to realize this great promise.”
- Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis Read more
- NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Read more
- Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
- Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
- Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more